Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology

About this update from Shanghai Fosun Pharmaceutical (group) Co., Ltd. Class A

[{"type":"list","items":[{"val":[{"type":"text","content":"Teva-engineered TEV-56278 is an anti-PD1-IL2 ATTENUKINE™ therapy in Phase 1 for the treatment of various forms of cancer, including melanoma","length":140,"tagName":"p"}]},{"val":[{"type":"text","content":"Fosun Pharma-Teva collaboration agreement established with goal of accelerating clinical data generation for TEV-56278","length":118,"tagName":"p"}]},{"val":[{"type":"text","content":"Partnership leverages strategic relationships to enable research and development of innovative treatments to advance Teva's Pivot to Growth strategy","length":157,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":415,"olType":false},{"type":"text","content":"TEL AVIV, Israel and SHANGHAI, June 16, 2025 /PRNewswire/ -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma", SSE: 600196, HKEX: 02196) today announced that the companies, through their respective subsidiaries, have entered a strategic partnership for the development of investigational TEV-56278, an anti-PD1-IL2 ATTENUKINE therapy.  Teva's internally developed ATTENUKINE technology provides a new mechanism of action, potentially offering high efficacy and low toxicity in a broad array of oncology indications.","length":611,"tagName":"p"},{"type":"text","content":"Under the terms of the agreement, which aims to accelerate clinical data generation, Fosun Pharma is granted an exclusive license to develop, manufacture and commercialize TEV-56278 in Chinese mainland, Hong Kong Special Administrative Region (SAR), Macau SAR and Taiwan region and select Southeast Asian countries.  Teva retains all development, manufacturing and commercialization rights to the licensed molecule in the rest of the world.  The strategic partnership presents a significant step forward in the global development of TEV-56278, giving Teva the opportunity to leverage Fosun Pharma-generated data in other geographies.","length":658,"tagName":"p"},{"type":"text","content":""This partnership with Fosun Pharma in the development of our internally developed TEV-56278, an anti-PD1-IL2 ATTENUKINE therapy with the potential to treat devastating cancers, is the latest advance to ensuring acceleration of our pipeline," said Eric Hughes, MD, PhD, Executi...

More updates from Shanghai Fosun Pharmaceutical (group) Co., Ltd. Class A